Optimizing hereditary angioedema management through tailored treatment approaches

Area of Science:

• Immunology
• Genetics
• Rare Diseases

Background:

• Hereditary angioedema (HAE) is a rare autosomal dominant disorder.
• It results from C1 esterase inhibitor (C1-INH) deficiency or dysfunction, leading to contact pathway activation.
• HAE attacks cause severe swelling, impacting quality of life and imposing socioeconomic burdens.

Purpose of the Study:

• To provide an overview of Hereditary Angioedema (HAE).
• To highlight the importance of early diagnosis and management.
• To discuss emerging treatments and patient-centered care approaches.

Main Methods:

• Literature review of HAE pathophysiology, clinical presentation, and management.
• Analysis of prevalence data and socioeconomic impact.
• Discussion of current and emerging therapeutic strategies.

Main Results:

• HAE affects approximately 1:50,000 individuals globally, with no racial predilection.
• Effective management strategies, including early treatment and prevention, significantly improve patient outcomes.
• New treatments and a shift towards patient-centered care are enhancing individualized treatment plans.

Conclusions:

• HAE is a serious condition requiring timely diagnosis and intervention.
• Optimized management, focusing on patient-centered care and novel therapies, is crucial for improving quality of life.
• Continued research and evidence development will further refine HAE treatment approaches.